BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 29330290)

  • 21. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1).
    Depoortere F; Pirson I; Bartek J; Dumont JE; Roger PP
    Mol Biol Cell; 2000 Mar; 11(3):1061-76. PubMed ID: 10712520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
    Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
    Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
    Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
    Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
    Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity.
    James MK; Ray A; Leznova D; Blain SW
    Mol Cell Biol; 2008 Jan; 28(1):498-510. PubMed ID: 17908796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depletion of SUMO ligase hMMS21 impairs G1 to S transition in MCF-7 breast cancer cells.
    Ni HJ; Chang YN; Kao PH; Chai SP; Hsieh YH; Wang DH; Fong JC
    Biochim Biophys Acta; 2012 Dec; 1820(12):1893-900. PubMed ID: 22906975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
    Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
    Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
    Hui R; Finney GL; Carroll JS; Lee CS; Musgrove EA; Sutherland RL
    Cancer Res; 2002 Dec; 62(23):6916-23. PubMed ID: 12460907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic anticipation by Cdk2/Cyclin A-bound p27 mediates signal integration in cell cycle regulation.
    Tsytlonok M; Sanabria H; Wang Y; Felekyan S; Hemmen K; Phillips AH; Yun MK; Waddell MB; Park CG; Vaithiyalingam S; Iconaru L; White SW; Tompa P; Seidel CAM; Kriwacki R
    Nat Commun; 2019 Apr; 10(1):1676. PubMed ID: 30976006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
    Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
    Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skp2-mediated p27(Kip1) degradation during S/G2 phase progression of adipocyte hyperplasia.
    Auld CA; Fernandes KM; Morrison RF
    J Cell Physiol; 2007 Apr; 211(1):101-11. PubMed ID: 17096381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27(Kip1).
    Alevizopoulos K; Catarin B; Vlach J; Amati B
    EMBO J; 1998 Oct; 17(20):5987-97. PubMed ID: 9774342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
    Le XF; Bedrosian I; Mao W; Murray M; Lu Z; Keyomarsi K; Lee MH; Zhao J; Bast RC
    Cell Cycle; 2006 Aug; 5(15):1654-61. PubMed ID: 16861913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4.
    Kardinal C; Dangers M; Kardinal A; Koch A; Brandt DT; Tamura T; Welte K
    Blood; 2006 Feb; 107(3):1133-40. PubMed ID: 16195327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
    Cai D; Byth KF; Shapiro GI
    Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
    AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes.
    Nahum A; Hirsch K; Danilenko M; Watts CK; Prall OW; Levy J; Sharoni Y
    Oncogene; 2001 Jun; 20(26):3428-36. PubMed ID: 11423993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incomplete folding upon binding mediates Cdk4/cyclin D complex activation by tyrosine phosphorylation of inhibitor p27 protein.
    Ou L; Ferreira AM; Otieno S; Xiao L; Bashford D; Kriwacki RW
    J Biol Chem; 2011 Aug; 286(34):30142-51. PubMed ID: 21715330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.